GCIMicrosaic Systems expands product range and market reach through Modern Water acquisition
[MicroTox bioluminescence. Image: Modern Water]
() a developer of microelectronic instruments and analytical solutions, issued a statement regarding its recently completed acquisition of water monitoring specialist Modern Water.
Microsaic said the Modern Water laboratory and production facilities have now been reactivated at Sand Hutton, England. Microsaic has re-engaged specialist staff and moved the business to a smaller and more cost-efficient part of the York Biotech Campus. Initial stocks of Modern Water's MicroTox reagents should be available for release by the end of February, with further reagents to be manufactured and available for shipping in April.
Microsaic has also begun marketing Sulphate Reducing Bacteria test kits (SRB Kits) and will be quality checking initial production in the coming weeks before making them available for purchase.
Separately, Microsaic reported "good progress" with the mass spectrometry part of its business. Outsourced manufacturing of the 4500MiD units continues at Kingfield Electronics in Chesterfield, England. Additionally, the company's mass spectrometer servicing capability has been set up in collaboration with a new partner Jaytee Biosciences in Herne Bay, Kent.
View from Vox
Microsaic's integration of Modern Water is moving along as planned. The acquisition of Modern Water's assets and the MicroTox water testing business previously owned by DeepVerge, was finalised on January 25 2024. is now actively resetting both the Modern Water and Microsaic Systems parts of its business to increase efficiency as key to its growth strategy. At the same time, the company is already receiving orders from existing repeat customers, and enquiries from those seeking to renew supplies of MicroTox for their testing equipment.
Microsaic says its initial focus in reconfiguring the business has been on growing markets in point of need environmental testing of water and for toxic and potentially carcinogenic chemicals. Its miniaturised PFAS detection equipment, built around the 4500MiD, is attracting significant market interest from OEMs and suppliers. A complete PFAS system is undergoing stage 1 testing with a large OEM in the US, estimated to complete in Q2 2024.
Investors should also expect an update "in due course" regarding the planned evaluation of Microsaic's bioprocessing solution, ProteinID, by a European OEM ahead of field trials expected later this year.
Follow News & Updates from Microsaic Systems:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.